These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12232712)

  • 21. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
    Feldman F; van Heertum R; Manos C
    Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
    Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
    Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
    Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
    J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
    Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
    AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.